PATENT CLAIM ANALYSIS

Application Number: 15884915
Application Type: Utility
Filing Date: 2018-01
Publication Date: 2018-08
Patent Classification: ["514", "676000"]

Abstract:
The present invention relates to a method of treating or preventing cellular dysfunction and death caused by genetic, degenerative, toxic, traumatic, ischemic, infectious, neoplastic and inflammatory diseases and aging—and their neurological symptoms and manifestations, which includes administering d-methadone, beta-d-methadol, alpha-l-methadol, beta-l-methadol, alpha-d-methadol, acetylmethadol, d-alpha-acetylmethadol, l-alpha-acetylmethadol, beta-d-acetylmethadol, beta-l-acetylmethadol, d-alpha-normethadol, l-alpha normethadol, noracetylmethadol, dinoracetylmethadol, methadol, normethadol, dinormethadol, EDDP, EMDP, d-isomethadone, normethadone, N-methyl-methadone, N-methyl-d-methadone, N-methyl-l-methadone, l-moramide, levopropoxyphene, pharmaceutically acceptable salts, or mixtures thereof, including deuterated and tritium analogues, whether isolated from its enantiomer or synthesized de novo.

Claim (Index 5):
The method of  claim 4 , wherein the second substance in combination with d-methadone is chosen from: NMDA channel blockers chosen from memantine, dextromethorphan, and amantadine; ketamine; (\u00b1)-5-(Aminocarbonyl)-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine hydrochloride (ADCI HCl); CGS 19755 (Selfotel); glycine/NMDA receptor antagonists chosen from 7-Chloro-4-hydroxy-3-(-3-phenoxyphenyl)-2(1H)quinoline (L 701,324); (+)-((R)-3-Amino-1-hydroxypyrrolidin-2-one [(+)-(R)-HA-966]; (\u00b1)-3-Amino-1-hydroxypyrrolidin-2-one [(\u00b1)-HA-966]; cholinesterase inhibitors; mood stabilizers; anti-psychotics; clozapine; CNS stimulants; amphetamines; anti-depressants; anxiolytics; lithium; magnesium; zinc; glutamine; glutamate; aspartame; aspartate; analgesics; opioidergic drugs; opioid antagonistschosen from naltrexone, nalmefene, naloxone, 1-naltrexol, dextronaltrexone, Nociceptin Opioid Receptor (NOP) antagonists, and selective k-opioid receptor antagonists; nicotine receptor agonists and nicotine; tauroursodeoxycholic acid (TUDCA); other bile acids, obethicolic acid, idebenone, phenylbutyric acid (PBA), other aromatic fatty acids, calcium-channel blockers, nitric oxide synthase inhibitors, levodopa, bromocriptine, other anti-Parkinson drugs, riluzole, edavarone, antiepileptic drugs, prostaglandins, beta-blockers, alpha-adrenergic agonist, carbonic anhydrase inhibitors, parasympathomimetics, epinephrine, hyperosmotic agents, hypoglycemic agents, antihypertensive agents, anti-ischemic agents, anti-obesity drugs, corticosteroids, immunosuppressants, and non steroidal anti-inflammatory drugs.

Metadata:
- Claim Count in Document: 29.0
- Percentile: 86.0
- Lexical Diversity: 1.53165
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['13803375', '15204052', '11527757', '13344393', '15579461']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7883790714558757
- 35 USC 102 Novelty (BERT): 0.5447733747434361
- Combined Prediction Score: 0.7640185017846317
- Mean Citation Score: 297.347038
- Max Citation Score: 403.17282
- Similarity Product: 276.5917378653073

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test